Transforming growth factor signalling: A common pathway in pulmonary arterial hypertension and systemic sclerosis

International Journal of Clinical Practice

Volumn 65, Issue SUPPL. 172, 2011, Pages 35-43

  Hatton, Nathan ^a   Frech, T ^a   Smith, B ^a   Sawitzke, A ^a   Scholand, M B ^a   Markewitz, B ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR;

AUTOIMMUNITY; CELL CYCLE ARREST; CELL PROLIFERATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONNECTIVE TISSUE DISEASE; DNA POLYMORPHISM; EPIGENETICS; FAMILY HISTORY; GENE MUTATION; GENETIC PREDISPOSITION; HEART DISEASE; HYPOXIA; LUNG DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PULMONARY CAPILLARY HEMANGIOMATOSIS; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

EID: 79960076306     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02726.x     Document Type: Review

References (84)

1. Simonneau G, Robbins IM, Beghetti M, et al., Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S43-54.
2. McLaughlin VV, Archer SL, Badesch DB, et al., ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
3. Rubin LJ,. Primary pulmonary hypertension. Chest 1993; 104: 236-50. (Pubitemid 23204564)
4. D'Alonzo GE, Barst RJ, Ayres SM, et al., Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-9.
5. van Wolferen SA, Marcus JT, Boonstra A, et al., Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-7. (Pubitemid 47343830)
6. Farber HW, Loscalzo J,. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-65.
7. Pietra GG, Capron F, Stewart S, et al., Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 25S-32S. (Pubitemid 38759714)
8. Jamison BM, Michel RP,. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum Pathol 1995; 26: 987-93.
9. Overbeek MJ, Vonk MC, Boonstra A, et al., Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J 2009; 34: 371-9.
10. Mukerjee D, St George D, Coleiro B, et al., Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-93. (Pubitemid 37323574)
11. Hachulla E, Gressin V, Guillevin L, et al., Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800. (Pubitemid 41798217)
12. Lee P, Langevitz P, Alderdice CA, et al., Mortality in systemic sclerosis (scleroderma). Q J Med 1992; 82: 139-48.
13. Hachulla E, Carpentier P, Gressin V, et al., Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinerAIR-Sclerodermie study. Rheumatology (Oxford) 2009; 48: 304-8.
14. McGoon M, Gutterman D, Steen V, et al., Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (Suppl. 1): 14S-34S. (Pubitemid 38932340)
15. Badesch DB, Raskob GE, Elliott CG, et al., Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137: 376-87.
16. Rich S, Dantzker DR, Ayres SM, et al., Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216-23. (Pubitemid 17137857)
17. Humbert M, Morrell NW, Archer SL, et al., Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43 (12 Suppl. S): 13S-24S. (Pubitemid 38759713)
18. Sztrymf B, Coulet F, Girerd B, et al., Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008; 177: 1377-83. (Pubitemid 351860916)
19. Deng Z, Morse JH, Slager SL, et al., Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-44. (Pubitemid 30659603)
20. Lane KB, Machado RD, Pauciulo MW, et al., Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81-4.
21. Trembath RC, Thomson JR, Machado RD, et al., Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 325-34. (Pubitemid 32703235)
22. Shovlin CL,. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-19.
23. Cogan JD, Pauciulo MW, Batchman AP, et al., High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 590-8. (Pubitemid 44330553)
24. Aldred MA, Vijayakrishnan J, James V, et al., BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006; 27: 212-3.
25. Thomson JR, Machado RD, Pauciulo MW, et al., Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000; 37: 741-5.
26. Machado RD, Aldred MA, James V, et al., Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006; 27: 121-32. (Pubitemid 43238027)
27. Machado RD, Eickelberg O, Elliott CG, et al., Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54 (Suppl. 1): S32-42.
28. Abenhaim L, Moride Y, Brenot F, et al., Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16. (Pubitemid 26277950)
29. Chin KM, Channick RN, Rubin LJ,. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130: 1657-63. (Pubitemid 46033416)
30. Garcia-Dorado D, Miller DD, Garcia EJ, Delcan JL, Maroto E, Chaitman BR,. An epidemic of pulmonary hypertension after toxic rapeseed oil ingestion in Spain. J Am Coll Cardiol 1983; 1: 1216-22. (Pubitemid 13059015)
31. Aeschlimann A, de Truchis P, Kahn MF,. Scleroderma after therapy with appetite suppressants. Report on four cases. Scand J Rheumatol 1990; 19: 87-90. (Pubitemid 20062489)
32. Allanore Y, Wipff J, Kahan A, Boileau C,. Genetic basis for systemic sclerosis. Joint Bone Spine 2007; 74: 577-83. (Pubitemid 350245624)
33. Valesini G, Litta A, Bonavita MS, et al., Geographical clustering of scleroderma in a rural area in the province of Rome. Clin Exp Rheumatol 1993; 11: 41-7. (Pubitemid 23050851)
34. Shinkai H,. Epidemiology of progressive systemic sclerosis in Japan. In:, Black CM, Myers AR, eds. Progressive Systemic Sclerosis (Current Topics in Rheumatology). New York: Gower, 1985: 79-81.
35. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J,. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223-35.
36. Silman AJ, Howard Y, Hicklin AJ, Black C,. Geographical clustering of scleroderma in south and west London. Br J Rheumatol 1990; 29: 93-6.
37. Tan FK, Tercero GM, Arnett FC, Wang N, Chakraborty R,. Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population. Arthritis Rheum 2003; 48: 3295-6. (Pubitemid 37409346)
38. Wang Y, Fan PS, Kahaleh B,. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006; 54: 2271-9. (Pubitemid 44051084)
39. Mora GF,. Systemic sclerosis: environmental factors. J Rheumatol 2009; 36: 2383-96.
40. Diot E, Lesire V, Guilmot JL, et al., Systemic sclerosis and occupational risk factors: a case-control study. Occup Environ Med 2002; 59: 545-9. (Pubitemid 34864549)
41. Garabrant DH, Lacey JV Jr, Laing TJ, et al., Scleroderma and solvent exposure among women. Am J Epidemiol 2003; 157: 493-500. (Pubitemid 36292907)
42. Silman AJ, Jones S,. What is the contribution of occupational environmental factors to the occurrence of scleroderma in men? Ann Rheum Dis 1992; 51: 1322-4. (Pubitemid 23000069)
43. Jimenez SA, Derk CT,. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 37-50. (Pubitemid 38055920)
44. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD,. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001; 44: 1359-62. (Pubitemid 32537534)
45. Englert H, Small-McMahon J, Chambers P, et al., Familial risk estimation in systemic sclerosis. Aust N Z J Med 1999; 29: 36-41. (Pubitemid 29136655)
46. Frech T, Khanna D, Markewitz B, Mineau G, Pimentel R, Sawitzke A,. Heritability of vasculopathy, autoimmune disease, and fibrosis in systemic sclerosis: a population-based study. Arthritis Rheum 2010; 62: 2109-16.
47. Feghali-Bostwick C, Medsger TA Jr, Wright TM,. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003; 48: 1956-63. (Pubitemid 36828691)
48. Zhou X, Tan FK, Xiong M, Arnett FC, Feghali-Bostwick CA,. Monozygotic twins clinically discordant for scleroderma show concordance for fibroblast gene expression profiles. Arthritis Rheum 2005; 52: 3305-14. (Pubitemid 41447114)
49. Fonseca C, Lindahl GE, Ponticos M, et al., A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med 2007; 357: 1210-20. (Pubitemid 47443180)
50. Tan FK, Wang N, Kuwana M, et al., Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001; 44: 893-901. (Pubitemid 32319782)
51. Wallis DD, Tan FK, Kielty CM, Kimball MD, Arnett FC, Milewicz DM,. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001; 44: 1855-64. (Pubitemid 32758234)
52. Neptune ER, Frischmeyer PA, Arking DE, et al., Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003; 33: 407-11. (Pubitemid 36278859)
53. Varga J, Pasche B,. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009; 5: 200-6.
54. Dieude P, Guedj M, Wipff J, et al., STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum 2009; 60: 2472-9.
55. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J,. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002; 29: 2379-81. (Pubitemid 35266029)
56. Tew MB, Arnett FC, Reveille JD, Tan FK,. Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum 2002; 46: 2829-30. (Pubitemid 36118956)
57. Selva-O'Callaghan A, Balada E, Serrano-Acedo S, Simeon Aznar CP, Ordi-Ros J,. Mutations of activin-receptor-like kinase 1 (ALK-1) are not found in patients with pulmonary hypertension and underlying connective tissue disease. Clin Rheumatol 2007; 26: 947-9. (Pubitemid 46951295)
58. Rahimi RA, Leof EB,. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007; 102: 593-608. (Pubitemid 47557414)
59. Nalbandian A, Crispin JC, Tsokos GC,. Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 2009; 157: 209-15.
60. Hannon GJ, Beach D,. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1994; 371: 257-61.
61. Mantel PY, Schmidt-Weber CB,. Transforming growth factor-beta: recent advances on its role in immune tolerance. Methods Mol Biol 2011; 677: 303-38.
62. Massague J,. TGF-beta signal transduction. Annu Rev Biochem 1998; 67: 753-91.
63. Hayes S, Chawla A, Corvera S,. TGF beta receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. J Cell Biol 2002; 158: 1239-49.
64. Seoane J,. Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 2006; 27: 2148-56.
65. Massague J, Seoane J, Wotton D,. Smad transcription factors. Genes Dev 2005; 19: 2783-810. (Pubitemid 41739965)
66. Gabrielli A, Avvedimento EV, Krieg T,. Scleroderma. N Engl J Med 2009; 360: 1989-2003.
67. Ihn H,. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci 2008; 49: 103-13. (Pubitemid 350298736)
68. Wu M, Varga J,. In perspective: murine models of scleroderma. Curr Rheumatol Rep 2008; 10: 173-82.
69. Whitfield ML, Finlay DR, Murray JI, et al., Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-24. (Pubitemid 37271558)
70. Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M,. Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum 2006; 54: 3011-21. (Pubitemid 44497783)
71. Kubo M, Ihn H, Yamane K, Tamaki K,. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731-4. (Pubitemid 32234634)
72. Takagi K, Kawaguchi Y, Kawamoto M, et al., Activation of the Activin A-ALK-Smad pathway in systemic sclerosis. J Autoimmun 2011; 36: 181-8.
73. Dong C, Zhu S, Wang T, et al., Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci USA 2002; 99: 3908-13. (Pubitemid 34252204)
74. Greenwel P, Inagaki Y, Hu W, Walsh M, Ramirez F,. Sp1 is required for the early response of alpha2(I) collagen to transforming growth factor-beta1. J Biol Chem 1997; 272: 19738-45. (Pubitemid 27340064)
75. Kucich U, Rosenbloom JC, Abrams WR, Rosenbloom J,. Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta, and p38. Am J Respir Cell Mol Biol 2002; 26: 183-8. (Pubitemid 34107871)
76. Taylor LM, Khachigian LM,. Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads. J Biol Chem 2000; 275: 16709-16. (Pubitemid 30398901)
77. You L, Kruse FE,. Differential effect of activin A and BMP-7 on myofibroblast differentiation and the role of the Smad signaling pathway. Invest Ophthalmol Vis Sci 2002; 43: 72-81. (Pubitemid 34032443)
78. Lai CF, Feng X, Nishimura R, et al., Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signaling. J Biol Chem 2000; 275: 36400-6.
79. Reynisdottir I, Polyak K, Iavarone A, Massague J,. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev 1995; 9: 1831-45.
80. Reddy KB, Howe PH,. Transforming growth factor beta 1-mediated inhibition of smooth muscle cell proliferation is associated with a late G1 cell cycle arrest. J Cell Physiol 1993; 156: 48-55. (Pubitemid 23211261)
81. Nishihara A, Watabe T, Imamura T, Miyazono K,. Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Mol Biol Cell 2002; 13: 3055-63. (Pubitemid 35034245)
82. Upton PD, Morrell NW,. TGF-beta and BMPR-II pharmacology-implications for pulmonary vascular diseases. Curr opin pharmacol 2009; 9: 274-80.
83. Pepper MS,. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8: 21-43. (Pubitemid 27214687)
84. Pardali E, ten Dijke P,. Transforming growth factor-beta signaling and tumor angiogenesis. Front biosci 2009; 14: 4848-61.